Investment
Features
FeesSafety
Academy
More
Pluang+

Compare First Trust NASDAQ Cybersecurity ETF (CIBR) vs Mesoblast Limited (MESO) Price & Performance

First Trust NASDAQ Cybersecurity ETFTrade
Mesoblast LimitedTrade

Price performance (Past 24H)

Key statistics

First Trust NASDAQ Cybersecurity ETF vs Mesoblast Limited — how do they compare? First Trust NASDAQ Cybersecurity ETF trades at $95.49, while Mesoblast Limited trades at $17.61 (market cap $2.12B). The key difference: First Trust NASDAQ Cybersecurity ETF is trading nearer its 52-week high, Mesoblast Limited nearer its low. Which is the better fit depends on your goals.

CIBRMESO
52-Week High
$94.73$20.96
52-Week Low
$60.74$10.96
Market Cap
$2.12B
Sector
Technology
Enterprise Value
$2.13B

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

First Trust NASDAQ Cybersecurity ETF

CIBR trades at $91.84, down 0.04% on the day, with a bullish technical signal from moving averages and a neutral stance from oscillators. The ETF has demonstrated strong performance, outperforming the S&P 500 by a three-to-one margin year-to-date, driven by robust cybersecurity spending trends. A dividend of $0.07 is scheduled for June 30, 2026. Recent news highlights institutional accumulation and positive momentum in the cybersecurity sector.

The outlook for CIBR is supported by growing global cybersecurity expenditures, projected to exceed $300 billion in 2026, and AI-driven demand. Risks include sector volatility and concentrated tech exposure. Analyst sentiment is positive, with recent upgrades citing reasonable valuation and secular growth, though investors should weigh high institutional interest against market cyclicality.

Mesoblast Limited

MESO trades at $16.22, up 5.05% today, with a bullish technical outlook from moving averages but mixed oscillators. The company shows strong gross margins of 80.52% but remains unprofitable with a net income margin of -144.33%. Recent news highlights commercial progress, including Ryoncil revenue of $36 million in Q4 2026 and pivotal Phase 3 trial milestones for chronic low back pain.

The outlook is cautiously optimistic, driven by FDA-approved Ryoncil's revenue growth and pipeline advancements, but high valuation (P/S 30.52) and persistent losses pose risks. Analyst consensus leans buy (45.46%), yet investors face volatility from clinical trial outcomes and cash burn concerns.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About First Trust NASDAQ Cybersecurity ETF

The fund will normally invest at least 90% of its net assets (including investment borrowings) in the common stocks and depositary receipts that comprise the index. The index includes securities of companies classified as cyber security companies. The fund is non-diversified.

Read more on CIBR

About Mesoblast Limited

Mesoblast Limited is a global leader in allogeneic cellular medicines. The company develops innovative, commercially-ready mesenchymal lineage cell (MLC) technology for the treatment of various inflammatory and cardiovascular conditions. Their pipeline focuses on leveraging the anti-inflammatory, tissue repair, and immune-modulating properties of these cells for diseases with high unmet medical needs, such as acute graft versus host disease (aGVHD) and chronic heart failure.

Read more on MESO